Erector Spinae Plane Block for Pain Control After Open Abdominal Surgery

Effect of Bilateral Erector Spinae Plane Block on Postoperative Opioid Consumption in Open Abdominal Surgeries Under General Anaesthesia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07479069

Enrollment

Registered

2026-03-18

Start date

2025-10-01

Completion date

2026-03-31

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain, Open Abdominal Surgery

Keywords

Erector Spinae Block

Brief summary

his randomized controlled trial aims to evaluate the efficacy of the bilateral erector spinae plane (ESP) block in reducing postoperative opioid consumption in patients undergoing open abdominal surgeries under general anesthesia

Detailed description

Patients undergoing abdominal surgeries experience severe postoperative pain. Conventional pain management methods, including opiates, may pose significant side effects. This study addresses the imperative need for optimizing postoperative pain management by systematically investigating the analgesic effects and complications associated with the bilateral ESP block. The study involves 46 patients allocated into two groups using a lottery method: a control group receiving standard pain control treatment, and an erector spinae block group receiving a bilateral ESP block in addition to standard pain control treatment. Pain intensity will be evaluated using a visual analogue scale (VAS) at 4, 8, 12, and 24 hours after the operation.

Interventions

PROCEDUREBilateral Erector Spinae Plane (ESP) Block

Administered after the induction of general anesthesia and before the surgical incision. Local anesthetic (0.25% ropivacaine or 0.25% bupivacaine) will be injected for a total of 20-40 mL

DRUGStandard Postoperative Analgesia

Patients receive 1000 mg of IV paracetamol every 6 hours postoperatively. If a patient experiences a Visual Analogue Score (VAS) of more than five at any time, they receive rescue analgesia in the form of nalbuphine 4mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiology (ASA) stage I-II. * Scheduled for abdominal surgery due to any indication.

Exclusion criteria

* History of Diabetes * History of neuropathic diseases * History of gastrointestinal bleeding, peptic ulcer, or inflammatory bowel disease * History of long-term nonsteroidal anti-inflammatory * History of chronic opioid analgesic use * History of severe hepatic or renal failure

Design outcomes

Primary

Measure	Time frame	Description
Postoperative Opioid Consumption	Within the first 24 hours after surgery	Assessed by the percentage of patients requiring rescue opioid analgesia. The need for rescue analgesia is determined by a Visual Analogue Score (VAS) greater than five

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026